Biological Activity
SZL P1-41 is Skp2 inhibitor, selectively suppresses Skp2 E3 ligase activity, but not activity of other SCF complexes.
In Vitro
SZL P1-41 also phenocopies the effects observed upon genetic Skp2 deficiency, such as suppressing survival, Akt-mediated glycolysis as well as triggering p53-independent cellular senescence. SZL P1-41 prevent Skp2-Skp1 interactions and Skp2 SCF E3 ligase activity. The reference concentration is 5 uM. SZL P1-41 restricts cancer cell survival through triggering p53-independent cellular senescence and inhibiting aerobic glycolysis.
In Vivo
SZL P1-41 exhibits potent anti-tumor activities in multiple animal models and cooperates with chemotherapeutic agents to reduce cancer cell survival.
References & source
[1]. Chan CH et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 2013 Aug 1;154(3):556-68.
[2]. Chan CH, et al. Skp2: a dream target in the coming age of cancer therapy. Cell Cy
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
